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ABSTRACT  
In last of 2019, the Centers for Disease Control and Prevention started monitoring the outbreak of a new corona virus, SARS-CoV-2, which 
causes the respiratory illness now known as COVID-19. Authorities first identified the virus in Wuhan, China. More than 82542 case of Corona 
virus in China at 31 March 2020. Health authorities have identified many other people with COVID-19 around the world. On 31 March 2020, the 
virus spread more than 750890 People in the World. The World Health Organization (WHO) has declared a public health emergency relating to 
COVID-19. Since then, this strain has been diagnosed in several residents of world. The CDC have advised that it is likely to sprea d to more 
people. COVID-19 has affected at least 213 countries or territories or areas. The first people with COVID-19 had links to an animal and seafood 
market. This fact suggested that animals initially transmitted the virus to humans. However, people with a more recent diagnosis had no 
connections with or exposure to the market, confirming that humans can pass the virus to each other. Corona viruses will infect most people at 
some time during their lifetime. Corona viruses can mutate effectively, which makes them so contagious. Information on the virus is scarce at 
present. In the past, respiratory conditions that develop from corona viruses, such as SARS and MERS, have spread through close contacts. On 
17 February 2020, the Director-General of the WHO presented at a media briefing the following updates on how often the symptoms of COVID-
19.However, while some viruses are highly contagious, it is less clear how rapidly corona viruses will spread. Symptoms vary from person-to-
person with COVID-19. It may produce few or no symptoms. However, it can also lead to severe illness and may be fatal. On 11 March 2020, 
WHO declared Novel Corona virus Disease (COVID-19) outbreak as a Pandemic. 
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In end of November and Starting of December 2019, few case 
of unknown Respiratory Infection was reported in Wuhan 
and Hubei, China. Its clinical characteristics are very similar 
to those of viral pneumonia. After analysis on respiratory 
samples, PRC Centers for Disease Control experts declared 
that the pneumonia, later known as novel corona virus 
pneumonia, was caused by novel corona virus1. WHO 
officially named the disease COVID-19. COVID-19 is a disease 
caused by a new strain of corona virus. ‘CO’ stands for 
corona, ‘VI’ for virus, and ‘D’ for disease. Formerly, this 
disease was referred to as ‘2019 novel corona virus’ or 
‘2019-nCoV.’The COVID-19 virus is a new virus linked to the 
same family of viruses as Severe Acute Respiratory 
Syndrome (SARS) and some types of common cold. 
International Committee on Taxonomy of Viruses (ICTV) 
named the virus severe acute respiratory syndrome corona 
virus 2 (SARS-CoV-2). On 11 March 2020, WHO 
declared Novel Corona virus Disease (COVID-19) outbreak as 
a pandemic and reiterated the call for countries to take 
immediate actions and scale up response to treat, detect and 
reduce transmission to save people’s lives. This virus belongs 
to β–corona virus, a large class of viruses prevalent in nature. 
Similar to other viruses, SARS-CoV-2 has many potential 
natural host, Intermediate host and final host. This poses 
great challenges to prevention and treatment of virus 
infection. this virus has high transmissibility and infectivity, 
but low mortality rate Compared with SARS and MERS,2. 
Genome analysis of novel corona virus sequences revealed 
that the complete genome sequence recognition rates of 
SARS-CoV and bat SARS corona virus (SARSr-CoV-RaTG13) 
were 79.5% and 96% respectively3. It implies that the corona 
virus might originate from bat. On 29 February 2020, data 
published by World Health Organization showed that, since 
31 March 2020 when the first case was  reported, 750890 
cases were Globally confirmed to be infected by novel corona 
virus and 36405 individuals were deaths  in total4. In the 
meantime, 1071 cases were confirmed, 29 were died in 
India4,5. It posed a great threat to global public health. This 
report reviews the genetic structure, infection source, 
transmission route, pathogenesis, clinical characteristics, and 
treatment and prevention of the SARS-CoV-2, so that it can 
provide references for follow-up research, prevention and 
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treatment, and may help readers to have the latest 
understanding of this new infectious disease. 
History 
The history of human corona viruses began in 1965 when 
Tyrrell and Bynoe6 found that they could passage a virus 
named B-814. It was found in human embryonic tracheal 
organ cultures obtained from the respiratory tract of an 
adult with a common cold. The presence of an infectious 
agent was demonstrated by inoculating the medium from 
these cultures in tranasally in human volunteers; colds were 
produced in a significant proportion of subjects, but Tyrrell 
and Bynoe were unable to grow the agent in tissue culture at 
that time. At about the same time, Hamre and Procknow7 
were able to grow a virus with unusual properties in tissue 
culture from samples obtained from medical students with 
colds. Both B814 and Hamre's virus, which she called 229E, 
were ether-sensitive and therefore presumably required a 
lipid-containing coat for infectivity, but these 2 viruses were 
not related to any known myxo- or paramyxoviruses. While 
working in the laboratory of Robert Chanock at the National 
Institutes of Health, McIntosh et al8 reported the recovery of 
multiple strains of ether-sensitive agents from the human 
respiratory tract by using a technique similar to that of 
Tyrrell and Bynoe. These viruses were termed “OC” to 
designate that they were grown in organ cultures. 
Within the same time frame, Almeida and Tyrrell9 performed 
electron microscopy on fluids from organ cultures infected 
with B814 and found particles that resembled the infectious 
bronchitis virus of chickens. The particles were medium 
sized (80–150 nm), pleomorphic, membrane-coated, and 
covered with widely spaced club-shaped surface projections.  
In the late 1960s, Tyrrell was leading a group of virologists 
working with the human strains and a number of animal 
viruses. These included infectious bronchitis virus, mouse 
hepatitis virus and transmissible gastroenteritis virus of 
swine, all of which had been demonstrated to be 
morphologically the same as seen through electron 
microscopy.10,11 This new group of viruses was named 
coronavirus (corona denoting the crown-like appearance of 
the surface projections) and was later officially accepted as a 
new genus of viruses.12 
Ongoing research using serologic techniques has resulted in 
a considerable amount of information regarding the 
epidemiology of the human respiratory corona viruses. It 
was found that in temperate climates, respiratory corona 
virus infections occur more often in the winter and spring 
than in the summer and fall. Data revealed that corona virus 
infections contribute as much as 35% of the total respiratory 
viral activity during epidemics. Overall, he proportion of 
adult colds produced by corona viruses was estimated at 
15%.13 
In the 3 decades after discovery, human strains OC43 and 
229E were studied exclusively, largely because they were the 
easiest ones to work with. OC43, adapted to growth in 
suckling mouse brain and subsequently to tissue culture, was 
found to be closely related to mouse hepatitis virus. Strain 
229E was grown in tissue culture directly from clinical 
samples. The 2 viruses demonstrated periodicity, with large 
epidemics occurring at 2- to 3-year intervals.14 Strain 229E 
tended to be epidemic throughout the United States, whereas 
strain OC43 was more predisposed to localized outbreaks. As 
with many other respiratory viruses, reinfection was 
common.15 Infection could occur at any age, but it was most 
common in children. 
Although the extensive focus placed exclusively on strains 
229E and OC43, it was clear that there were other corona 
virus strains as well. As shown by Bradburne,16 corona virus 
strain B814 was not serologically identical with either OC43 
or 229E. Contributing to the various strain differences in the 
family of coronaviruses, McIntosh et al17 found that 3 of the 6 
strains previously identified were only distantly related to 
OC43 or 229E. 
Epidemiologic and volunteer inoculation studies found that 
respiratory coronaviruses were associated with a variety of 
respiratory illnesses; however, their pathogenicity was 
considered to be low.7,13,18,19 The predominant illness 
associated with infections was an upper respiratory infection 
with occasional cases of pneumonia in infants and young 
adults.20,21 These viruses were also shown to be able to 
produce asthma exacerbations in children as well as chronic 
bronchitis in adults and the elderly.22,23 
While research was proceeding to explore the pathogenicity 
and epidemiology of the human corona viruses, the number 
and importance of animal corona viruses were growing 
rapidly. Corona viruses were described that caused disease 
in multiple animal species, including rats, mice, chickens, 
turkeys, calves, dogs, cats, rabbits and pigs. Animal studies 
included, but were not limited to, research that focused on 
respiratory disorders. Study focus included disorders such as 
gastroenteritis, hepatitis and encephalitis in mice; 
pneumonitis and sialodacryoadenitis in rats; and infectious 
peritonitis in cats. Interest peaked particularly regarding 
areas of encephalitis produced by mouse hepatitis virus and 
peritonitis produced by infectious peritonitis virus in cats. 
Pathogenesis of these disease states was various and 
complex, demonstrating that the genus as a whole was 
capable of a wide variety of disease mechanisms.25 Human 
and animal corona viruses were segregated into 3 broad 
groups based on their antigenic and genetic makeup. Group I 
contained virus 229E and other viruses, group II contained 
virus OC43 and group III was made up of avian infectious 
bronchitis virus and a number of related avian viruses.26 
Types of Corona Virus 
Different types of human corona viruses vary in how severe 
the resulting disease becomes, and how far they can spread. 
Physician currently recognize seven types of corona virus 
that can infect humans.  
Common types  
1. 229E (alpha coronavirus)  
2. NL63 (alpha coronavirus)  
3. OC43 (beta coronavirus)  
4. HKU1 (beta coronavirus)  
Rarer strains that cause more severe complications include 
MERS-CoV, which causes Middle East respiratory syndrome 
(MERS), and SARS-CoV, the virus responsible for severe 
acute respiratory syndrome (SARS). In 2019, a dangerous 
new strain called SARS-CoV-2 started circulating, causing the 
disease COVID-1927. 
Taxonomy 
Corona viruses belong to the sub-family Coronavirinae in the 
family Coronaviridae. The scientific name for coronavirus is 
Orthocoronavirinae or Coronavirinae.28,29,30 Corona viruses 
belong to the family of Coronaviridae, order Nidovirales, and 
realm Riboviria31,32 They are divided into alpha corona 
viruses and betacoronaviruses which infect mammals – and 
gamma corona viruses and delta corona viruses which 
primarily infect birds.33  
 Genus: Alphacoronavirus  
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o Species: Human coronavirus 229E, Human coronavirus 
NL63, Miniopterus bat coronavirus 1, Miniopterus bat 
coronavirus HKU8, Porcine epidemic diarrhea virus, 
Rhinolophus bat coronavirus HKU2, Scotophilus bat 
coronavirus  
 Genus Betacoronavirus;[51] type species: Murine 
coronavirus  
o Species: Betacoronavirus 1 (Bovine Coronavirus, Human 
coronavirus OC43), Human coronavirus HKU1, Murine 
coronavirus, Pipistrellus bat coronavirus HKU5, 
Rousettus bat coronavirus HKU9, Severe acute 
respiratory syndrome-related coronavirus (SARS-CoV, 
SARS-CoV-2), Tylonycteris bat coronavirus HKU4, Middle 
East respiratory syndrome-related coronavirus, 
Hedgehog coronavirus 1 (EriCoV) 
 Genus Gammacoronavirus; type species: Infectious 
bronchitis virus  
o Species: Beluga whale coronavirus SW1, Infectious 
bronchitis virus 
 Genus Deltacoronavirus; type species: Bulbul 
coronavirus HKU11  
o Species: Bulbul coronavirus HKU11, Porcine coronavirus 
HKU15 
Outbreaks of Human Corona Virus Diseases 
 Severe acute respiratory syndrome (SARS) 
In 2003, following the outbreak of severe acute respiratory 
syndrome (SARS) which had begun the prior year in Asia, 
and secondary cases elsewhere in the world, the World 
Health Organization (WHO) issued a press release stating 
that a novel corona virus identified by a number of 
laboratories was the causative agent for SARS. The virus was 
officially named the SARS corona virus (SARS-CoV). More 
than 8,000 people were infected, about ten percent of whom 
died.34  
Middle East respiratory syndrome (MERS) 
In September 2012, a new type of corona virus was 
identified, initially called Novel Corona virus 2012, and now 
officially named Middle East respiratory syndrome corona 
virus (MERS-CoV).35,36 The World Health Organization issued 
a global alert soon after.37 The WHO update on 28 September 
2012 said the virus did not seem to pass easily from person 
to person.38 However, on 12 May 2013, a case of human-to-
human transmission in France was confirmed by the French 
Ministry of Social Affairs and Health.39 In addition, cases of 
human-to-human transmission were reported by the 
Ministry of Health in Tunisia. Two confirmed cases involved 
people who seemed to have caught the disease from their 
late father, who became ill after a visit to Qatar and Saudi 
Arabia. Despite this, it appears the virus had trouble 
spreading from human to human, as most individuals who 
are infected do not transmit the virus.40 By 30 October 2013, 
there were 124 cases and 52 deaths in Saudi Arabia.41 
After the Dutch Erasmus Medical Centre sequenced the virus, 
the virus was given a new name, Human Corona virus—
Erasmus Medical Centre (HCoV-EMC). The final name for the 
virus is Middle East respiratory syndrome corona virus 
(MERS-CoV). The only U.S. cases (both survived) were 
recorded in May 2014.42 
In May 2015, an outbreak of MERS-CoV occurred in the 
Republic of Korea, when a man who had traveled to the 
Middle East, visited four hospitals in the Seoul area to treat 
his illness. This caused one of the largest outbreaks of MERS-
CoV outside the Middle East.43As of December 2019, 2,468 
cases of MERS-CoV infection had been confirmed by 
laboratory tests, 851 of which were fatal, a mortality rate of 
approximately 34.5%.44  
Clinical Symptoms  
Dry Cough, Cold, Sore Throat, High Fever ( 1020C-1030C) 
these symptoms usually Show in from 2–4 days after a 
corona virus infection. However, symptoms vary from 
person-to-person, and some forms of the virus can be fatal. 
45,46 
Symptoms include:  
1. Sneezing  
2. Runny nose  
3. Dry Cough  
4. Watery diarrhea  
5. Fever  
6. Sore Throat  
7. Exacerbated asthma  
8, Breathlessness   
 It may take 2–14 days for a person to notice symptoms after 
infection.  





• Loss of smell or taste 
• Fatigue 
• Ongoing chest pain or pressure  
• confusion  
• Can’t wake up fully  
• Bluish lips or face 
If you’re infected, symptoms can show up in as few as 2 days 
or as many as 14. It varies from person to person. According 
to researchers in China, these were the most common 
symptoms among people who had COVID-19 49,50 
• Fever 83%-99% 
• Cough 59%-82% 
• Fatigue 44%-70% 
• Lack of appetite 40%-84% 
• Shortness of breath 31%-40% 
• Mucus/phlegm 28%-33% 
• Body aches 11%-35% 
Corona viruses can spread in the following ways:  
Coughing and sneezing without covering the mouth can 
disperse droplets into the air. Touching or shaking hands 
with a person who has the virus can pass the virus between 
individuals. Making contact with a surface or object that has 
the virus and then touching the nose, eyes, or mouth. Some 
animal corona viruses, such as feline corona virus (FCoV), 
may spread through contact with feces. However, it is 
unclear whether this also applies to human corona viruses. 
The National Institutes of Health (NIH) suggest that several 
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groups of people have the highest risk of developing 
complications due to COVID-19.  
These groups include:  
1. Young children  
2. People aged 65 years or older  
3. Women who are pregnant  
Sneezing can also help prevent transmission. It is important 
to dispose of any tissues after use and maintain hygiene 
around the home.  
People can catch COVID-19 from others who have the virus. 
The disease can spread from person to person through small 
droplets from the nose or mouth which are spread when a 
person with COVID-19 coughs or exhales. These droplets 
land on objects and surfaces around the person. Other people 
then catch COVID-19 by touching these objects or surfaces, 
then touching their eyes, nose or mouth. People can also 
catch COVID-19 if they breathe in droplets from a person 
with COVID-19 who coughs out or exhales droplets. This is 
why it is important to stay more than 1 meter (3 feet) away 
from a person who is sick.51,52  
Prevent the spread of disease  
Virus spreads from person to person, it’s important to limit 
your contact with other people as much as possible. Some 
people work in “essential businesses” that are vital to daily 
life, such as health care, law enforcement, and public utilities. 
Everyone else should stay home as much as you can. You 
might hear officials use these terms when they talk about 
staying home53,54,55: 
• Social distancing or physical distancing, keeping space 
between yourself and other people when you have to go out 
• Quarantine , keeping someone home and separated from 
other people if they might have been exposed to the virus 
• Isolation , keeping sick people away from healthy people, 
including using a separate “sick” bedroom and bathroom 
when possible 
Reduce chances of Spreading COVID-19 by taking 
some simple precautions: 
• Regularly and thoroughly clean your hands with an alcohol-
based hand rub or wash them with soap and water. 
• Maintain at least 1 metre (3 feet) distance between yourself 
and anyone who is coughing or sneezing.When someone 
coughs or sneezes they spray small liquid droplets from their 
nose or mouth which may contain virus. If you are too close, 
you can breathe in the droplets, including the COVID-19 
virus if the person coughing has the disease. 
• Avoid touching eyes, nose and mouth, Hands touch many 
surfaces and can pick up viruses. Once contaminated, hands 
can transfer the virus to your eyes, nose or mouth. From 
there, the virus can enter your body and can make you sick. 
• Make sure you, and the people around you, follow good 
respiratory hygiene. This means covering your mouth and 
nose with your bent elbow or tissue when you cough or 
sneeze. Then dispose of the used tissue immediately. 
• Stay home if you feel unwell. If you have a fever, cough and 
difficulty breathing, seek medical attention and call in 
advance. Follow the directions of your local health authority. 
• Keep up to date on the latest COVID-19 hotspots (cities or 
local areas where COVID-19 is spreading widely). If possible, 
avoid traveling to places  – especially if you are an older 
person or have diabetes, heart or lung disease. 
Protection measures for persons who are in or 
have recently visited (past 14 days) areas where 
COVID-19 is spreading 
• Follow the guidance outlined above (Protection measures 
for everyone)                                        
• Self-isolate by staying at home if you begin to feel unwell, 
even with mild symptoms such as headache, low grade fever 
(37.3 C or above) and slight runny nose, until you recover. 
Avoiding contact with others and visits to medical facilities 
will allow these facilities to operate more effectively and help 
protect you and others from possible COVID-19 and other 
viruses. 
• If you develop fever, cough and difficulty breathing, seek 
medical advice promptly as this may be due to a respiratory 
infection or other serious condition. Call in advance and tell 
your provider of any recent travel or contact with travelers. 
Corona virus life cycle Steps  
1. Attachment and entry  
2. Replicase protein expression  
3. Replication and transcription  
4. Assembly and release. 
  
 
Figure 1: Life cycle of Corona virus 
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Genetic structure and pathogenic mechanism of 
SARS-CoV-2 
 Corona virus (COV) is a single strand RNA virus with a 
diameter of 80-120nm. It is divided into four types: α-corona 
virus (α-COV), β-corona virus (β-COV), δ-corona virus (δ-
COV) and γ – corona virus (γ-COV)56. Six corona viruses 
were previously known to cause disease in humans, SARS-
CoV-2 is the seventh member of the corona virus family that 
infects human beings after SARS-CoV and MERS-CoV57.SARS-
CoV-2, like SARS-CoV and MERS-CoV, belongs to β-corona 
virus. The genome sequence homology of SARS-CoV-2 and 
SARS is about 79%, the 2019-nCoV is closer to the SARS-like 
bat CoVs (MG772933) than the SARS-CoV58, which is 
descended from SARS-like bat CoVs. Interestingly, for high 
similarity of receptor-binding domain (RBD) in Spike-
protein, several analyses reveal that SARS-CoV-2 uses 
angiotension-converting enzyme 2 (ACE2) as receptor, just 
like as SARS-CoV59. Corona virus mainly recognizes the 
corresponding receptor on the target cell through the S 
protein on its surface and enters into the cell, then causing 
the occurrence of infection. A structure model analysis 
shows that SARS-CoV-2 binds ACE2 with above 10 folds 
higher affinity than SARS-CoV, but higher than the threshold 
required for virus infection60. The detailed mechanism about 
whether the SARS-CoV-2 would infect humans via binding of 
S-protein to ACE2, how strong the interaction is for risk of 
human transmission, and how SARS-CoV-2 causes 
pathological mechanisms of organs damage remains 
unknown, which need more studies to elaborate. These 
results further explains the more rapid transmission 
capability of the SARS-CoV-2 in humans than SARS-CoV, and 
the number of confirmed COVID-19 much higher than people 
with SARS-CoV infection. Considering the higher affinity of 
SARS-CoV-2 binds ACE2, soluble ACE2 might be a potential 
candidate for COVID-19 treatments. 
 
 
Figure 2:  Genetic structure of corona Virus 
 
Prevalence of SARS-CoV-2 
Basic Reproduction Number (R0) refers to the average 
amount of secondary infection that patients may produce in 
completely susceptible population without intervention61. 
The estimation of R0 varies among different research teams 
and is updated as more information is exposed. Wu, JT, 
Leung et al. of York University estimated the R0 of novel 
corona virus to be 2.47-2.8662 using the SEIR model. 
Majumder of Boston Children’s Hospital and his colleagues 
adjusted R0 to be 2.0-3.3 using the IDEA model63. The R0 
value of other viruses of β – corona virus, such as SARS-CoV, 
is estimated to be 2.2-3.664. The R0 value of MERS-CoV is 
estimated to be 2.0-6.765. These indicate that SARS-CoV-2 has 
relatively high transmissibility. Population is generally 
susceptible to SARS-CoV-2, the median age was  47.0 years 
(IQR, 35.0 to 58.0), 87% case patients were 30 to 79 years of 
age, and 3% were age 80 years or older, and the number of 
female patients was 41.9%66,67. Most cases were diagnosed in 
Hubei Province, China (75%). 81% cases were classified as 
mild, 14% cases were severe, and 5% were critical. The 
overall case-fatality rate (CFR) was 2.3%, but cases in those  
aged 70 to 79 years had an 8.0% CFR and cases in those aged 
80 years and older had a 14.8%  CFR68. This implies that 
elderly male citizens are more susceptible to this corona 
virus as compared with other groups, and this virus is more 
likely to affect elderly male citizens with chronic underlying 
diseases.69 In summary, COVID-19 is high in prevalence and 
population is generally susceptible to such virus, and COVID-
19 rapidly spread from a single Wuhan city to the entire 
country in just 30 days. So that prompt measures should be 
taken to control the spread of the disease. 
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Clinical characteristics of SARS-CoV-2 infection 
COVID-19 produces an acute viral infection in humans with 
median incubation period was 3.0 days 66, which is similar to 
the SRAS with an incubation period ranging from 2–10 
days82. The presenting features of COVID-19 infection in 
adults are pronounced. The presenting features in adults are 
pronounced. The most common clinical symptoms of SARS-
CoV-2 infection were fever (87.9%), cough (67.7%), fatigue 
(38.1%), whereas diarrhea  (3.7%) and vomiting (5.0%) 
were rare66,83 which were similar to others corona virus. 
Most patients had some degree of dyspnoea at presentation, 
because the time from onset of symptoms to the 
development of acute respiratory distress syndrome (ARDS) 
was only 9 days among the initial patients with COVID-19 
infection1. Moreover, severe patients are prone to a variety of 
complications, including acute respiratory distress 
syndrome, acute heart injury and secondary infection67. 
There are already some evidences that COVID-19 can cause 
damage to tissues and organs other than the lung. In a study 
of 214 COVID-19 patients,69 (36.4%) patients had 
neurological manifestations84. In addition, there is already 
evidence of ocular surface infection in patients with COVID-
19, and SARS-CoV-2 RNA was detected in eye secretions of 
patient85. Some COVID-19 patients have arrhythmia, acute 
heart injury, impaired renal function, and abnormal liver 
function (50.7%) at admission1,86,87. A case report of the 
pathological manifestations of a patient with pneumonia 
showed moderate microvesicular steatosis in his liver 
tissue88. Besides, tissue samples of stomach, duodenum, and 
rectal mucosa were confirmed positive for SARS-CoV-2 
RNA90. In general, the radiographical features of corona virus 
are similar to those found in community-acquired 
pneumonia caused by other organisms90. Chest CT scan is 
important tool to diagnose this pneumonia. Nevertheless, 
several typical imaging features are frequently observed in 
COVID-19 pneumonia, including the predominant 
groundglass opacity (65%), consolidations (50%), smooth or 
irregular interlobular septal thickening (35%), air 
bronchogram (47%), and thickening of the adjacent pleura 
(32%), with predominantly peripheral and lower lobe 
involvement91. A recent study reported that most patients 
(90%) had bilateral chest CT findings and the sensitivity of 
chest CT to suggest COVID-19 was 97%85. Combining chest 
CT imaging features with clinical symptom and laboratory 
test could facilitate early diagnosis of COVID-19 pneumonia. 
Laboratory examination revealed that 82.1% of patients was 
lymphopenia and 36.2% of patients was thrombocytopenia. 
Most patients had normal leukocytes, but leukopenia was 
observed in 33.7% of patients. In addition, most patients 
demonstrated elevated levels of C-reactive protein（CRP）, 
lactate dehydrogenase (LDH）and creatinine kinase（CK）, 
but minority of patients had elevated transaminase, 
abnormal myocardial enzyme spectrum, or elevated serum 
creatinine1,75. As compared with bacterial pneumonia, 
patients with SARS-CoV-2 showed lower oxygenation index. 
Cytokine release syndrome is a vital factor that aggravates 
disease progression. A higher levels of IL-6 and IL-10, and 
lower levels of CD4+T and CD8+T are observed in COVID-19 
patients parallel with the severity of the disease 92. 
 Treatment of SARS-CoV-2  
There is no specific antiviral treatment recommended for 
COVID-19, and no vaccine is currently available. The 
treatment is symptomatic, and oxygen therapy represents 
the major treatment intervention for patients with severe 
infection. Mechanical ventilation may be necessary in cases 
of respiratory failure refractory to oxygen therapy, whereas 
hemodynamic support is essential for managing septic 
shock.  
On 28 January 2020, the WHO released a document 
summarizing WHO guidelines and scientific evidence derived 
from the treatment of previous epidemics from HCoVs. This 
document addresses measures for recognizing and sorting 
patients with severe acute respiratory disease; strategies 
for infection prevention and control; early supportive 
therapy and monitoring; a guideline for laboratory diagnosis; 
management of respiratory failure and ARDS; management 
of septic shock; prevention of complications; treatments; 
and considerations for pregnant patients.      
(A)  Antiviral Allopathic treatment 
At present, the treatments of patients with SARS-CoV-2 
infection are mainly symptomatic treatments. Remdesivir 
was recently reported as a promising antiviral drug against a 
wide array of RNA viruses. Holshue et al. for the first time 
reported that treatment of a patient with COVID-19 used 
remdesivir and achieved good results97. Then, Xiao et al. 
findings reveal that remdesivir effectively in the control of 
2019-nCoV infection in vitro. Meanwhile, also found that 
chloroquine has an immune-modulating activity and could 
effectively inhibit in this virus in vitro98 . Clinical controlled 
trials have shown that Chloroquine was proved to be 
effective in the treatment of patients with COVID-1999. 
Remdesivir is undergoing a large number of clinical trials in 
several hospitals, and the final efficacy of the drug is 
uncertain. Arbidol, a small indole derivative molecule, was 
found to block viral fusion against influenza A and B viruses 
and hepatitis C viruses100 and confirmed to have antiviral 
effect on SARS-CoV in cell experiment101, so that it might be a 
choice for COVID-19 treatment. The randomized controlled 
study on treatment of novel corona virus by Arbidol and 
Kaletra undertaken at present showed that Arbidol had 
better therapeutic effect than Kaletra did and could 
significantly reduce the incidence of severe cases. Apart from 
the above, lopinavir/ritonavir, nucleoside analogues, 
neuraminidase inhibitors, remdesivir, and peptide EK1 could 
also be the choices of antiviral drugs for COVID-19 
treatment103 
(B) Ayurvedic Treatment 
 The Treatment of patients Show SARS-CoV-2 mild Symptom. 
Formulations like Lakshmi Vilas Rasa104, Pippali rasayana105, 
Sanjeevani vati, Chitrakadi vati, Go jihvaadi Kashaya, Vyaghri 
haritaki, Kantakaari Avaleha, Dashamul kwath, Sitopaladi106, 
Talishadi, and Yashtimadhu may be the most suitable drugs 
to be used at this stage in an integrative model.  Population 
where the moderate to severe symptoms are present and the 
patients also belong to high risk . These patients require 
tertiary care from the beginning itself but can also be co-
prescribed with Ayurveda medicines in order to reduce the 
impact of the pathology and to buy more time to have 
intensive management107. Recommended formulations here 
may include Pippali rasayana105, Laghu Vasant Malati, 
Sanjeevani vati, Tribhuvan keerti rasa108, Brihata Vata 
Chintamni rasa, Mrityunjaya rasa, and Siddha makardhvaja 
rasa. The key criterion for choosing rasa aushadhi in 
category 3 and 4 as noted above is the urgency of initiation of 
therapeutic actions. Rasaaushadi are shown to have better 
bioavailability and absorption through sublingual and oral 
route accounting to the nano size of their particles109. For 
example, suvarna bhasma has been found to get absorbed 
well through sublingual administration when mixed with 
black pepper powder and ghee110. 
(C) Homoeopathic Treatment 
 The Health advisory given by Ministry of AYUSH against 
corona virus infection included Homoeopathic medicine 
Arsenicum album – 30 as a possible preventive for flu like 
illness such as coronavirus infection.111 Scientific Advisory 
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Board considered that the same medicine has been advised 
for prevention of Influenza Like Illness112,113. Arsenic album 
as one of the constituents in a formulation has been shown to 
affect HT29 cells and human macrophages.  Bryonia, 
Beryllium, Lobelia purpurescens114  is another homoeopathic 
medicine helpful to patient suffer with the flu-like symptoms 
(D) Unani Treatment  
Unani system of medicine has its roots in ancient Greece, in 
the teachings of Hippocrates (460–377 BCE). The name 
Unani reflects its Hellenistic origin and is derived from the 
Yunan, the ancient name of Greece. Unani medicine 
flourished to its zenith during medieval ages (500–1500 CE) 
in the Muslim world, mostly in the Arabian peninsula, Persia, 
Egypt, Syria, ancient Mesopotamia, etc. Ergo it is also 
referred to as Greco-Arabian medicine and Persian medicine 
in different parts of theworld . In India, it is integrated into 
the national healthcare systemand officially named as Unani 
medicine. Unanimedicine is based on the Hippocratic 
concepts of mizaj (temperament) and akhlat (humors). Unani 
Medicines that may help in the symptomatic management of 
coronavirus, Drugs prescribed in Unani medicine for nazla-e-
wabaiya (epidemic influenza) were Behidana,Unnab, 
Sapistan, Khaksi, Habb-ul-aas, Tabasheer, Tukhm-e-Kahu, 
Elwa, Za'fran.  
Unani medicine does not mention epidemics and pandemics 
as separate entities, and a common term ‘waba’ is used for 
those diseases which affect a large geographical area. This is 
probably for two reasons, first and foremost, global 
communication was not possible in medieval ages like today; 
and second, travel over very long distances would have 
rarely occurred, hence the occurrence of a pandemic would 
have been a remote possibility, practically unlikely115.  
(E) Immuno enhancement therapy 
Synthetic recombinant interferon α has proven to be 
effective in treatment of SARS patients in clinic trials116. 
Pulmonary X-ray abnormal remission time was reduced by 
50% in the interferon-treated group compared with the 
glucocorticoid-treated group alone. Interferon was also 
found to be an effective inhibitor of MERS-CoV replication117. 
Those findings suggested that interferon could be used in the 
treatment of COVID-19. Intravenous immunoglobulin might 
be the safest immune-modulator for long-term use in all ages, 
and could help to inhibit the production of pro-inflammatory 
cytokines and increase the production of anti-inflammatory 
mediators118. Moreover, Thymosin alpha-1 (Ta1) can be an 
immune booster for SARS patients, effectively controlling the 
spread of disease119. Intravenous immunoglobulin and Ta1 
may also be considered as therapeutics for COVID-19. 
(F)  Plasma therapy 
When there are no sufficient vaccines and specific drugs, 
convalescent plasma therapy could be an effective way to 
alleviate the course of disease for severely infected 
patients120. In a retrospective analysis, convalescent plasma 
therapy is more effective than severe doses of hormonal 
shock in patients with severe SARS, reducing mortality and 
shortening hospital stays121. A prospective cohort study by 
Hung and colleagues showed that for patients with pandemic 
H1N1 influenza virus infection in 2009, the relative risk of 
death was significantly lower in patients treated with 
convalescent plasma122. Moreover, from the perspective of 
immunology, most of the patients recovered from COVID-19 
would produce specific antibodies against the SARS-CoV-2, 
and their serum could be used to prevent reinfection. At the 
same time, antibodies can limit the virus reproduction in the 
acute phase of infection and help clear the virus, which is 
conducive to the rapid recovery of the disease123. 
Theoretically, viremia peaks during the first week of most 
viral infections, and it should be more effective to give 
recovery plasma early in the disease123. Therefore, the 
plasma of some patients recovered from COVID-19 could be 
collected to prepare plasma globulin specific to SARS-CoV-2. 
However, the safety of plasma globulin products specific to 
SARS-CoV-2 deserves further consideration. 
(G) Auxiliary Blood purification treatment 
At present, extracorporeal blood purification technology in 
the treatment of severe NCP patients92 According to the 
latest studies85, ACE2, the key receptor of SARS-CoV-2, is 
highly expressed in human kidney (nearly 100 times higher 
than that in lung). Kidney might be main target of attack for 
novel corona virus. Early continuous blood purification 
treatment could reduce renal workload and help to promote 
the recovery of renal function125. Most of the severe patients 
with novel corona virus might suffer from cytokine storm. 
The imbalance of pro-inflammatory factors and anti-
inflammatory factors might cause immune damage. 
Therefore, blood purification technology could be used to 
remove inflammatory factors, eliminate cytokine storm, 
correct electrolyte imbalance, and maintain acid-base 
balance, to control patient’s capacity load in an effective 
manner126. In this logic, the patient's symptoms could be 
improved and the blood oxygen saturation could be 
increased. 
In summary, the drug treatment for COVID-19 mainly 
comprised four ways, i.e., antiviral Western medicine, 
Chinese medicine, immune-enhancement therapy, and viral 
specific plasma globulin. Machines could be used as auxiliary 
therapy. However, randomized double-blind large sample 
clinical trial should be served as the standard to determine 
whether the antiviral drugs could be used in clinical practice. 
(I) Corona virus Vaccine 
 There’s no vaccine, but intense research has been underway 
around the world since scientists shared the virus’ genetic 
makeup in January 2020. Vaccine testing in humans started 
with record speed. UK government formed a COVID-19 
vaccine taskforce to stimulate British efforts for rapidly 
developing a vaccine through collaborations of industry, 
universities, and government agencies across the vaccine 
development pipeline, including for clinical trial placement 
at UK hospitals, regulations for approval, and eventual 
manufacturing.127 The vaccine development initiatives at the 
University of Oxford and Imperial College of London.128,129  
France, CEPI announced a US$4.9 million investment in a 
COVID-19 vaccine research consortium involving the Institut 
Pasteur, Themis Bioscience (Vienna, Austria), and the 
University of Pittsburgh, bringing CEPI's total investment in 
COVID-19 vaccine development to US$480 million in 
May.130,131 In March, the European Commission provided an 
€80 million investment in CureVac, a German biotechnology 
company, to develop a mRNA vaccine.132 Belgium, Norway, 
Switzerland, Germany, and the Netherlands have been major 
contributors to the CEPI effort for COVID-19 vaccine 
research in Europe.133 U.S. Biomedical Advanced Research 
and Development Authority (BARDA) a federal agency that 
funds disease-fighting technology, announced investments of 
nearly US$1 billion to support American COVID-19 vaccine 
development, and preparation for manufacturing the most 
promising candidates. BARDA made a US$483 million 
investment in the vaccine developer, Moderna and its 
partner, Johnson & Johnson.133,134 BARDA has an additional 
US$4 billion to spend on vaccine development, and will have 
roles in other American investment for development of six to 
eight vaccine candidates to be in clinical studies over 2020-
21 by companies, such as Sanofi Pasteur and Regeneron.135 
Nine Chinese COVID-19 vaccines in development, involving 
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1,000 scientists and Chinese research institutes and military 
hospitals.136 Three Chinese vaccine companies and research 
institutes are supported by the government for financing 
research, conducting clinical trials, and manufacturing the 
most promising vaccine candidates, while prioritizing rapid 
evidence of efficacy over safety.137 
(H) Monoclonal Antibodies   
Chunyan Wang et al. were first to report that 47D11 (human) 
monoclonal antibody that neutralizes SARS-CoV-2. Research 
reports declaring that the 47D11 binds a conserved epitope 
on the spike receptor-binding domain and cross-neutralize 
SARSCoV-2. The cross-reactive nature of 47D11 shows that 
the antibody is more possible to target the conserved core 
structure of the S1B receptor binding domain. Hence these 
neutralizing antibodies can reduce the course of virus action 
inthe host or defend an uninfected host that is exposed to the 
virus138 . Tian et al. reported that the RBD of SARS-Cov-2 
differs largely from the SARS-CoV at the C-terminus residues. 
Their results implied that SARS-CoV specific neutralizing 
antibodies such as m396, CR3014 that target the receptor-
binding domain of SARS-CoV ineffective to bind SARS-Cov-2 
spike protein. Their research report stating that the antibody 
CR3022 completely neutralized both the wild-type SARS-CoV 
and SARS-Cov-2 at a concentration of 23.5 μg/ml. Tian et al. 
suggested that CR3022 can be used as a potential 
therapeutics, alone or in combination with other neutralizing 
antibodies, for the prevention and treatment of SARS-Cov-2 
infections 139. 
Monoclonal antibodies could provide a strategy for 
emergency prophylaxis and SARS-CoV-2 therapy, while 
alternative and more time consuming development of 
vaccines and new drugs are underway.  As a result, SARS-
CoV-2 neutralizing antibodies may be used to prevent 
infection in people exposed to SARS-CoV-2, such as hospital 
staff caring for suspected SARS-CoV-2 patients, and may also 
be used for early treatment of infected individuals to prevent 
the onset of serious SARS-CoV-2 disease and to reduce the 
chance of spreading the virus to exposed individuals. 
Conclusion  
Human history is observing a very strange time fighting an 
invisible enemy, Over the past 50 years the emergence of 
many different corona viruses that cause a wide variety of 
human diseases has occurred. It is likely that these viruses 
will continue to emerge and to evolve and cause human 
outbreaks owing to their ability to recombine, mutate, and 
infect multiple species and cell types. WHO declared Novel 
Corona virus Disease (COVID-19) outbreak as a pandemic on 
11 March 2020. Future research on corona viruses will 
continue to investigate many aspects of viral Symptom, 
Spread, Life cycle, replication and pathogenesis. This review 
provides an insight into the COVID-19 current situation and 
represents a picture of the current state of the art in terms of 
public health impact, pathophysiology and clinical 
manifestations, diagnosis, case management, emergency 
response and preparedness. Understanding the propensity of 
these viruses to jump between species, to establish infection 
in a new host and to identify significant reservoirs of corona 
viruses will dramatically aid in our ability to predict when 
and where potential epidemics may occur. As bats seem to be 
a significant reservoir for these viruses, it will be interesting 
to determine how they seem to avoid clinically evident 
disease and become persistently infected. Many of the non-
structural and accessory proteins encoded by these viruses 
remain uncharacterized with no known function, and it will 
be important to identify mechanisms of action for these 
proteins as well as defining their role in viral replication and 
pathogenesis. These article helpful for Identification of 
corona patient on the basis of Symptom and the best practice 
for the management and treatment of symptomatic cases & 
stop Spreading of COVID-19. 
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